NCT01182194View on ClinicalTrials.gov

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Healthy
Interventions
DRUG

Drospirenone/Ethinyl Estradiol (Gianvi®)

3 mg/0.02 mg Tablets

DRUG

YAZ®

3 mg/0.02 mg Tablets

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT01182194 - Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions. | Biotech Hunter | Biotech Hunter